

103.00



#813
RECEIVED

OCT 02 2002
10/11/02

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE CENTER 1600/2900

Applicant : Weers et al.

Appl. No. : 09/888,311

Filed : June 22, 2001

For : PHOSPHOLIPID BASED
POWDERS FOR
INHALATION

Examiner : E. Webman

) Group Art Unit 1617

) I hereby certify that this correspondence and all
) marked attachments are being deposited with the
) United States Postal Service as first-class mail in
) an envelope addressed to: Assistant
) Commissioner for Patents, Washington, D.C.
) 20231, on

9/24/02
(Date)

Kathy Honnert
Kathy Honnert

AMENDMENT

Assistant Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

In response to the Office Action dated June 25, 2002 please consider the following amendments and remarks with respect to the above-captioned application.

IN THE CLAIMS

Please amend the claims as follows:

Please cancel claims 1 - 3 and 13.

B 21. A method for inhalation of a dry powder drug comprising:
administering a dry powder drug composition comprising particles comprising a
phospholipid matrix and a particle size of 1-30 microns, mass median aerodynamic diameter of
less than 5 microns, and bulk density of less than 0.5 g/cm³ from a passive dry powder inhaler
wherein the emitted dose of said composition exiting from said passive dry powder inhaler after a
single inspiratory effort is at least 80% w/w and is substantially independent over an inhalation
flow rate of 20-90 l/min and device resistance of 0.04-0.20 (cmH₂O)^{1/2} /L min⁻¹.